Tg Therapeutics (TGTX) Leases (2019 - 2025)
Tg Therapeutics has reported Leases over the past 7 years, most recently at $6.3 million for Q4 2025.
- Quarterly results put Leases at $6.3 million for Q4 2025, down 11.9% from a year ago — trailing twelve months through Dec 2025 was $6.3 million (down 11.9% YoY), and the annual figure for FY2025 was $6.3 million, down 11.9%.
- Leases for Q4 2025 was $6.3 million at Tg Therapeutics, down from $6.5 million in the prior quarter.
- Over the last five years, Leases for TGTX hit a ceiling of $9.1 million in Q1 2021 and a floor of $6.3 million in Q4 2025.
- Median Leases over the past 5 years was $8.4 million (2023), compared with a mean of $8.1 million.
- Biggest five-year swings in Leases: grew 3.36% in 2022 and later fell 12.38% in 2025.
- Tg Therapeutics' Leases stood at $8.6 million in 2021, then increased by 3.0% to $8.9 million in 2022, then dropped by 9.43% to $8.0 million in 2023, then decreased by 11.17% to $7.2 million in 2024, then decreased by 11.9% to $6.3 million in 2025.
- The last three reported values for Leases were $6.3 million (Q4 2025), $6.5 million (Q3 2025), and $6.7 million (Q2 2025) per Business Quant data.